Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort

BMC Neurology

Volumn 6, Issue , 2006, Pages

  Guerreiro, Rita J ^a,b   Bras, Jose M ^a,b   Santana, Isabel ^c   Januario, Cristina ^c   Santiago, Beatriz ^c   Morgadinho, Ana S ^c   Ribeiro, Maria H ^c   Hardy, John ^a   Singleton, Andrew ^a   Oliveira, Catarina ^b,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; HFE PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PORTUGAL; RISK FACTOR; SCREENING TEST; STATISTICAL SIGNIFICANCE; WILD TYPE;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COGNITION DISORDERS; COHORT STUDIES; COMORBIDITY; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; IRON METABOLISM DISORDERS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PORTUGAL; SAMPLE SIZE; SEX DISTRIBUTION;

EID: 33747179546     PISSN: 14712377     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-6-24     Document Type: Article

References (25)

1. Bomford A: Genetics of haemochromatosis. The Lancet 2002, 360(9346):1673-1681.
2. O'Neil J, Powell L: Clinical Aspects of hemochromatosis. Semin Liver Dis 2005, 25(4):381-91.
3. Le Gac G, Ferec C: The molecular genetics of haemochromatosis. Eur J Hum Genet 2005, 13(11):1172-1185.
4. Casetta I, Govoni V, Granieri E: Oxidative Stress, Antioxidants and Neurodegenerative Diseases. Curr Pharm Des 2005, 11(16):2033-52.
5. Zhu X, Lee HG, Casadesus G, Avila J, Drew K, Perry G, Smith MA: Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 2005, 31(1-3):205-17.
6. Moreira PI, Siedlak SL, Aliev G, Zhu X, Cash AD, Smith MA, Perry G: Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 2005, 112(7):921-32.
7. Pulliam JF, Jennings CD, Kryscio RJ, Davis DG, Wilson D, Montine TJ, Schmitt FA, Markesbery WR: Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet 119(1)-48-53. 2003 May 15
8. Kaur D, Andersen J: Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res Rev 2004, 3(3):327-43.
9. Jenner P: Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53(Suppl 3):S26-36.
10. Dekker MC, Giesbergen PC, Njajou OT, van Swieten JC, Hofman A, Breteler MM, van Duijn CM: Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci Lett 2003, 348(2):117-9.
11. Buchanan DD, Silburn PA, Chalk JB, Le Couteur DG, Mellick GD: The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci Lett 2002, 327(2):91-4.
12. Berlin D, Chong G, Chertkow H, Bergman H, Phillips NA, Schipper HM: Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging 2004, 25(4):465-74.
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th revised edition Washington, DC; 1994.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
15. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
16. Morris JC: The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993, 43:2412-2414.
17. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterisation and outcome. Archives of Neurology 1999, 56:303-308.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease. A clinico-pathological study of 100 cases. JNNP 1992, 55:181-184.
19. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43(8):1467-72.
20. Borie C, Gasparini F, Verpillat P, Bonnet AM, Agid Y, Hetet G, Brice A, Durr A, Grandchamp B: Association study between iron related genes polymorphisms and Parkinson's disease. J Neurol 2002, 249:801-804.
21. Candore G, Licastro F, Chiappelli M, Franceschi C, Lio D, Rita Balistreri C, Piazza G, Colonna-Romano G, Grimaldi LM, Caruso C: Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy. Mech Ageing Dev 2003, 124(4):525-8.
22. Moalem S, Percy ME, Andrews DF, Kruck TP, Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC: Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 2000, 93(1):58-66.
23. Combarros O, Garcia-Roman M, Fontalba A, Fernandez-Luna JL, Llorca J, Infante J, Berciano J: Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease. Dement Geriatr Cogn Disord 2003, 15(3):151-4.
24. Sampietro M, Caputo L, Casatta A, Meregalli M, Pellagatti A, Tagliabue J, Annoni G, Vergani C: The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging 2001, 22(4):563-8.
25. Robson KJ, Lehmann DJ, Wimhurst VL, Livesey KJ, Combrinck M, Merryweather-Clarke AT, Warden DR, Smith AD: Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet 2004, 41(4):261-5.